Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Death
研究概览
简要总结
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
详细描述
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.
Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.
A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult aged >=18years old;
- •Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
- •Diagnosed with primary hypertension.
- •Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.
排除标准
- •Near-death state (expected survival time less than 24 hours);
- •Malignant tumor;
- •Pregnancy or puerperium women;
- •ACEI contraindication
- •Patients who refused to participant.
结局指标
主要结局
Death
时间窗: up to 28 days
The number of patients who died of 2019-nCoV infection.
Occupancy rate in the intensive care unit (ICU)
时间窗: up to 28 days
The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
Mechanical Ventilation
时间窗: up to 28 days
The number of patients requiring mechanical ventilation.
次要结局
- All cause mortality(up to 28 days)
- Time to Clinical Recovery(up to 28 days)
- Time from onset of symptoms to main outcome and its components(up to 28 days)
研究者
Dongying Zhang
Associate Professor
Chongqing Medical University